Of high translational relevance, the first description of a sustained therapeutic response was recently reported in a patient with polycythemia and multiple inoperable PGL caused by a mosaic germline EPAS1 variant who was treated with belzutifan, a selective small-molecule inhibitor of HIF2α (Kamihara et al. 2021). Here, EPAS1 is linked to polycythemia.